Guoxing Liu

Guoxing Liu

Auto-generated profile, based on publicly available information

Guoxing Liu

Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The 2ndXiangya Hospital, Central South University, Changsha, Hunan Province, 410011, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CXChengzhi Xie
Chengzhi Xie
GLGuoxing Liu
Guoxing Liu
MLMin Li
Min Li
YFYu Fang
Yu Fang
KQKe Qian
Ke Qian
XXXundi Xu
Xundi Xu
The landscape of cellular plasticity and sources with relevant niche signals in hepatocellular carcinoma is still obscure. Transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel, is involved in a variety of malignancies and overexpressed in hepatocellular carcinoma (HCC). We have investigated the role of TRPV1 in HCC from different angles by various experimental techniques, such as in vivo and in vitro experiments, and by bioinformatics analysis of data from genetic models induced by diethylnitrosamine (DEN), mice samples and human HCC samples. We find that TRPV1 knockout promotes to hepatocarcinogenesis and deconstructs the portal triad adjacent to tumor border that is contributed by originations of tumor initiating cells and biliary cells. Epithelial to mesenchymal transition (EMT) is involved and transcription factors Ovol2 and Zeb1 coordinated with Sox 10 drive gene expression in the event which is also confirmed by the expression of these proteins in human HCC samples. Treatment with TRPV1 agonist Capsaicin inhibits the growth of HCC cells in xenograft models. Our findings demonstrate that TRPV1 is a potential therapeutic target in human HCC and exerts effects on cellular plasticity with modulation of Ovol2, Zeb1 and Sox10.

1 January 2018 in Life Sciences
Verified
Journal Article
Closed access
GLGuoxing Liu
Guoxing Liu
CXChengzhi Xie
Chengzhi Xie
YFYu Fang
Yu Fang
KQKe Qian
Ke Qian
QLQiang Liu
Qiang Liu
XXXundi Xu
Xundi Xu

11 June 2012 in Oncology Letters
Verified
Journal Article
Open access
PDF file
CXChengzhi Xie
Chengzhi Xie
GLGuoxing Liu
Guoxing Liu
JLJiefeng Liu
Jiefeng Liu
ZHZhao Huang
Zhao Huang
FWFusheng Wang
Fusheng Wang
XXXundi Xu
Xundi Xu
In our previous study, we reported that the cannabinoid receptors CB1 and CB2 are overexpressed in human hepatocellular carcinoma (HCC) tissues. Recently, the antitumor potential of the endogenous cannabinoid anandamide (AEA) has also been addressed. The present study was conducted to investigate the anti-proliferative effects of AEA in HCC cells. The human HCC cell line Huh7 was used. Cell proliferation was measured by MTT assay and flow cytometry. Apoptotic analysis was investigated by TUNEL assay. Real-time PCR and western blot analysis were used to analyze the expression of relevant molecules. The results of this study demonstrated that AEA inhibited the proliferation of Huh7 cells, resulted in G1 cell cycle arrest and induced apoptosis. Furthermore, downregulation of CDK4 and upregulation of p21 and Bak by AEA were observed. This study defines the anti-proliferative effects of anandamide in HCC cells and suggests that AEA has therapeutic potential in the management of HCC patients.